NCT01168713 - Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia | Biotech Hunter

Enrollment

132

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions

Community-Acquired Bacterial Pneumonia

Interventions

DRUG

Levofloxacin

"Levofloxacin once daily for 5 days:~Levofloxacin 750 mg PO Days 1-5"

DRUG

CEM-101

"CEM-101 once daily for 5 days:~CEM-101 800 mg PO Day 1~CEM-101 400 mg PO Days 2-5"

Trial Locations (55)

19611

West Reading

29681

Simpsonville

30513

Blue Ridge

31406

Savannah

31904

Columbus

32605

Gainesville

32713

DeBary

32837

Orlando

33012

Hialeah

34741

Kissimmee

35242

Birmingham

37067

Franklin

44304

Akron

45005

Carlisle

48202

Detroit

49684

Traverse City

52001

Dubuque

57702

Rapid City

59701

Butte

61550

Morton

70112

New Orleans

75110

Corsicana

77002

Houston

77093

Houston

78238

San Antonio

83404

Idaho Falls

84020

Draper

84044

Magna

84121

Salt Lake City

86001

Flagstaff

89109

Las Vegas

90015

Los Angeles

90201

Bell Gardens

90501

Torrence

90650

Norwalk

91105

Pasadena

91763

Montclaire

91911

Chula Vista

91942

LeMesa

92056

Oceanside

93030

Oxnard

97404

Eugene

06708

Waterbury

02720

Fall River

02740

New Bedford

T2N2T9

Calgary

L8N3Z5

Hamilton

L8N4A6

Hamilton

L8V1C3

Hamilton

K1Y 4E9

Ottawa

M9W 4L6

Toronto

G7H-5H6

Chicoutimi

J7Z5T3

Saint-Jérôme

J1H5N4

Sherbrooke

G8Z3R9

Trios-Rivieres